†Incomplete doses have been reported with Neulasta® Onpro® due to the device not performing as intended. This may increase risk of neutropenia, FN, and/or infection.
Neulasta® is also available in prefilled syringe for manual injection
Neulasta® Onpro® is available at no extra cost beyond that of the Neulasta® prefilled syringe
For more information regarding dosing, please see the Neulasta® full Prescribing Information.
G-CSF = granulocyte colony-stimulating factor.
The information provided does not replace the Healthcare Provider Instructions
Use. Prior to use, please review the Instructions for Use.
The patient educational video gives patients an overview of Neulasta® and how the on-body injector for Neulasta® works.
This video does not replace the Instructions for Use. Please consult the
Instructions for Use when using the Neulasta® Onpro® kit.
If additional adhesion is deemed appropriate, an adhesive extender that fits around the on-body injector can be obtained.
(Select option 2, then option 3)
Neulasta® stimulates neutrophil development in the bone marrow, which may lead to bone pain for some patients.3-6
|Event||Placebo (n = 461)||Neulasta® 6 mg SC on day 2 (n = 467)|
|Pain in extremity||4%||9%|
Taxane therapy may be associated with bone pain.2
Treatment with loratadine may be considered to help prevent bone pain in patients receiving chemotherapy and pegfilgrastim.4
Randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine versus no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. The primary endpoint of the study was bone pain (all grades combined) in cycle 1, captured as part of AE reporting.4
SC = subcutaneous; AE = adverse event.
Amgen continues to provide resources and solutions that support your patients and your practice
Comparable Neulasta® pharmacokinetics with the prefilled syringe (PFS) for manual injection and on-body injector1
PFS = prefilled syringe; SD = standard deviation.
Study design: Phase 1, randomized, open-label study of Neulasta® pharmacokinetics in healthy subjects at 5 controlled study centers. Subjects were randomized to receive a single, 6-mg dose of Neulasta® by hand using the PFS for manual injection (n = 128) or automatically using the on-body injector (n = 125). Primary endpoints were the maximum Neulasta® concentration and area under the concentration curve from time 0 to infinity after dosing.1
Acute Respiratory Distress Syndrome (ARDS)
Serious Allergic Reactions
Allergies to Acrylics
Use in Patients With Sickle Cell Disorders
Capillary Leak Syndrome (CLS)
Potential for Tumor Growth Stimulatory Effects on Malignant Cells
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients With Breast and Lung Cancer
Potential Device Failures
Most common adverse reactions
Please see Neulasta® full Prescribing Information.
Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.
Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta® (Neulasta® Onpro® kit).
Special Instructions for the On-body Injector (OBI) for Neulasta®
A healthcare provider must fill the on-body injector (OBI) with Neulasta® using the co-packaged prefilled syringe and then apply the OBI to the patient’s skin (abdomen or back of arm). The back of the arm may only be used if there is a caregiver available to monitor the status of the OBI. Approximately 27 hours after the OBI is applied to the patient’s skin, Neulasta® will be delivered over approximately 45 minutes. A healthcare provider may initiate administration with the OBI on the same day as the administration of cytotoxic chemotherapy, as long as the OBI delivers Neulasta® no less than 24 hours after the administration of cytotoxic chemotherapy.
The prefilled syringe co-packaged in the Neulasta® Onpro® kit contains additional solution to compensate for liquid loss during delivery through the OBI. If this syringe is used for manual subcutaneous injection, the patient will receive an overdose. If the prefilled syringe for manual use is used with the OBI, the patient may receive less than the recommended dose.
Do not use the OBI to deliver any other drug product except the Neulasta® prefilled syringe co-packaged with the OBI. Use of the OBI has not been studied in pediatric patients.
The OBI should be applied to intact, non-irritated skin on the arm or abdomen.
A missed dose could occur due to an OBI failure or leakage. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for a replacement dose of pegfilgrastim if they suspect that the device may not have performed as intended. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use as soon as possible after detection.
Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient.
Refer to the Healthcare Provider Instructions for Use for the OBI for full administration information.
1. Yang BB, et al. Cancer Chemother Pharmacol. 2015;75:1199-1206. 2. Kirshner JJ, et al. Support Care Cancer. 2018;26:1323-1334. 3. Neulasta® (pegfilgrastim) Prescribing Information, Amgen. 4. Yang BB, et al. Clin Pharmacokinet. 2011;50:295-306. 5. Haegerstam GA. Acta Orthop Scand. 2001;72:308-317. 6. Schweizerhof M, et al. Nat Med. 2009;15:802-807.
1. Data on file, Amgen; 2021. 2. Data on file, Amgen; 2020. 3.Weycker D, et al. J Oncol Pharm Pract. 2014;20:190-198. 4. Vogel CL, et al. J Clin Oncol. 2005;23:1178-1184.5. American Cancer Society. Watching for and Preventing Infections. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/preventing-infections-in-people-with-cancer.html. Accessed August 15, 2022. 6. Neulasta® (pegfilgrastim) Prescribing Information, Amgen.
1. Data on file, Amgen; 2021. 2. Rifkin RM, et al. Support Care Cancer. 2022;1-10. doi: 10.1007/s00520-022-07226-9. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloid Growth Factors V.1.2021. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 5, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Data on file, Amgen; 2020. 5. Lyman GH. J Natl Comr Canc Netw. 2009;7:2612-2615.
1. Data on file, Amgen; ; 2022. 2. Data on file, Amgen; ; 2022.
1. Data on file, Amgen; ; 2020. 2. Data on file, Amgen; ; 2020. 3. Data on file, Amgen; ; 2020. 4. Data on file, Amgen; 2016. 5. Vogel CL, et al. J Clin Oncol. 2005;23(6):1178-1184.
1. Data on file, Amgen; 2021. 2. NEUPOGEN® (filgrastim) Prescribing Information, Amgen. 3. Neulasta® (pegfilgrastim) Prescribing Information, Amgen. 4. Data on file, Amgen; ; 2020. 5. Data on file, Amgen; ; 2020. 6. Data on file, Amgen; 2016. 7. Vogel CL, et al. J Clin Oncol. 2005;23(6):1178-1184. 8. Data on file, Amgen; ; 2020.
1. Data on file, Amgen; ; 2020. 2. Data on file, Amgen; ; 2020. 3. Vogel CL, et al. J Clin Oncol. 2005;23(6):1178-1184. 4. Data on file, Amgen; 2021. 5. Rifkin RM, et al. Support Care Cancer. 2022;1-10. doi: 10.1007/s00520-022-07226-9. 6. Data on file, Amgen; 2022.